Centre hospitalier de l'Université de Montréal (CHUM)
chumontreal.qc.caLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
365
Active
106
Phase 3
14
Total enrollment
121,627
Pipeline matrix
Showing 30 of 30 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Intravenous unfractionated heparin | — | — | — | — | — | 1 | |
| N-13 ammonia intravenous | — | — | — | — | — | 1 | |
| IV Acetaminophen | — | — | — | — | — | 1 | |
| Mepolizumab 100 MG | — | — | — | — | — | 1 | |
| Triamcinolone Acetonide | — | — | — | — | — | 1 | |
| Aprepitant 40mg | — | — | — | — | — | 1 | |
| F-choline intravenous | — | — | — | — | — | 1 | |
| Topical Infliximab | — | — | — | — | 2 | ||
| Cannabis oil vs placebo | — | — | — | — | — | 1 | |
| LDX-01 plus TAU | — | — | — | — | — | 1 | |
| Mycophenolate Mofetil | — | — | — | — | — | 1 | |
| Fostemsavir | — | — | — | — | — | 1 | |
| Cannabis, placebo | — | — | — | — | — | 1 | |
| Trazodone 25 mg | — | — | — | — | — | 1 | |
| Treatment as Usual plus Placebo | — | — | — | — | — | 1 | |
| Treatment as Usual plus Placebo plus Contingency Management | — | — | — | — | — | 1 | |
| Treatment as Usual plus lisdexamfetamine | — | — | — | — | — | 1 | |
| Treatment as Usual plus lisdexamfetamine (LDX-01) plus Contingency Management | — | — | — | — | — | 1 | |
| ∆9-tetrahydrocannabinol | — | — | — | — | — | 1 | |
| FMT + ICI | — | — | — | — | — | 1 | |
| Topical insulin | — | — | — | — | — | 1 | |
| Artificial tears | — | — | — | — | — | 1 | |
| KAN-004 | — | — | — | — | — | 1 | |
| PEGLyte bowel preparation | — | — | — | — | — | 1 | |
| Triamcinolone Hexacetonide and hyaluronic acid | — | — | — | — | — | 1 | |
| Triamcinolone Hexacetonide | — | — | — | — | — | 1 | |
| Antiplatelet Agents | — | — | — | — | — | 1 | |
| Ketamine | — | — | — | — | — | 1 | |
| Cemiplimab | — | — | — | — | — | 1 | |
| Dupilumab | — | — | — | — | — | 1 |
Next readouts
- 2024-08-20
- 2024-09-01
- 2025-04-10
- 2025-08-15
- 2025-12
- 2026-06
- 2026-07-01
- 2026-07-31
- 2026-09
- 2026-09-01
Top conditions
- Lung Cancer16
- Colorectal Cancer9
- Polyp of Colon7
- Pain7
- Glaucoma6
- Anesthesia6
- Postoperative Pain6
- Prostate Cancer6
Frequently asked questions about Centre hospitalier de l'Université de Montréal (CHUM)
- How many clinical trials does Centre hospitalier de l'Université de Montréal (CHUM) have on ClinicalTrials.gov?
- Centre hospitalier de l'Université de Montréal (CHUM) is listed as the lead sponsor on 365 clinical trials in ClinicalTrials.gov, 106 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Centre hospitalier de l'Université de Montréal (CHUM)'s trials are in Phase 3?
- 14 of Centre hospitalier de l'Université de Montréal (CHUM)'s trials are in Phase 3, spread across 30 active drug programs.
- What therapeutic areas does Centre hospitalier de l'Université de Montréal (CHUM) focus on?
- Centre hospitalier de l'Université de Montréal (CHUM)'s most-studied conditions on ClinicalTrials.gov are Lung Cancer, Colorectal Cancer, Polyp of Colon, Pain, Glaucoma.
- When are Centre hospitalier de l'Université de Montréal (CHUM)'s next clinical trial readouts?
- Centre hospitalier de l'Université de Montréal (CHUM) has 10 upcoming primary-completion readouts tracked here; the soonest is “Safety of Topical Insulin Drops for Open-angle Glaucoma”, expected around 2024-08-20.